SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10642	Companies
226315	Keywords
154810	Articles
119796	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 03/10/2025 at 21:09, 1 year 3 months ago

Sanofi: Disclosure of trading in own shares
PRESS RELEASE

published on 03/10/2025 at 21:09, 1 year 3 months ago

Sanofi : Déclaration des transactions sur actions propres
BRIEF

published on 03/08/2025 at 19:05, 1 year 3 months ago

Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid

Clinical Study Dupixent Type 2 Inflammation Bullous Pemphigoid Regulatory Review
BRIEF

published on 03/08/2025 at 19:05, 1 year 3 months ago

Sanofi-Aventis publie des données positives sur Dupixent dans le traitement de la pemphigoïde bulleuse

Étude Clinique Dupixent Pemphigoïde Bulleuse Examen Réglementaire Inflammation De Type 2
PRESS RELEASE

published on 03/08/2025 at 19:00, 1 year 3 months ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Positive pivotal data for Dupixent in bullous pemphigoid presented at AAD, showing significant disease remission and reduction in severity, itch, and medication use. Regulatory submissions under review in US and EU

Dupixent Type 2 Inflammation Bullous Pemphigoid AAD Sustained Remission
BRIEF

published on 02/25/2025 at 07:05, 1 year 4 months ago

Sarclisa Gains Approval in Japan for Multiple Myeloma Treatment

Multiple Myeloma Sarclisa Approval Sanofi Oncology Japan Healthcare IMROZ Study
BRIEF

published on 02/25/2025 at 07:05, 1 year 4 months ago

Sarclisa obtient l'approbation au Japon pour le traitement du myélome multiple

Myélome Multiple Étude IMROZ Approbation De Sarclisa Sanofi Oncologie Système De Santé Au Japon
PRESS RELEASE

published on 02/25/2025 at 07:00, 1 year 4 months ago

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for newly diagnosed multiple myeloma patients, offering new treatment options based on positive IMROZ phase 3 study results

Oncology Japan Multiple Myeloma Sarclisa IMROZ Study
PRESS RELEASE

published on 02/24/2025 at 21:27, 1 year 4 months ago

Sanofi : Déclaration des transactions sur actions propres
PRESS RELEASE

published on 02/24/2025 at 21:27, 1 year 4 months ago

Sanofi: Disclosure of trading in own shares

Accesswire

Published on 06/26/2026 at 01:40, 6 hours 58 minutes ago

UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 9 hours 8 minutes ago

Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 10 hours 8 minutes ago

Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 11 hours 6 minutes ago

BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 17 hours 8 minutes ago

Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 08:00, 38 minutes ago

MHM Corporate: Debt Restructuring through Bonds Redeemable in Shares
Published on 06/26/2026 at 08:00, 38 minutes ago

MHM Corporate: Restructuration de sa dette par voie d'obligations remboursables en actions
Published on 06/26/2026 at 07:30, 1 hour 8 minutes ago

REINET INVESTMENTS S.C.A. ANNOUNCES REVISED DATE FOR ANNUAL GENERAL MEETING
Published on 06/26/2026 at 07:30, 1 hour 8 minutes ago

THE NAGA GROUP AG CONFIRMS FY 2025 REVENUES AND REPORTS STRONGER-THAN-EXPECTED EBITDA
Published on 06/26/2026 at 07:30, 1 hour 8 minutes ago

Pyrum Innovations AG reports results for the first three months of 2026

Les Echos

Published on 06/26/2026 at 07:00, 1 hour 38 minutes ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 1 hour 38 minutes ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 13 hours 53 minutes ago

Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 14 hours 8 minutes ago

Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 14 hours 48 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE